Literature DB >> 24928387

Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Monika A Davare1, Sangeet Lal2, Jennifer L Peckham2, Suresh I Prajapati3, Sakir H Gultekin4, Brian P Rubin5, Charles Keller6.   

Abstract

Leptomeningeal metastasis is a cause of morbidity and mortality in medulloblastoma, but the understanding of molecular mechanisms driving this process is nascent. In this study, we examined the secretory chemokine profile of medulloblastoma cells (DAOY) and a meningothelial cell line (BMEN1). Conditioned media (CM) of meningothelial cells increased adhesion, spreading and migration of medulloblastoma. VEGFA was identified at elevated levels in the CM from BMEN1 cells (as compared to DAOY CM); however, recombinant VEGFA alone was insufficient to enhance medulloblastoma cell migration. In addition, bevacizumab, the VEGFA scavenging monoclonal antibody, did not block the migratory phenotype induced by the CM. These results reveal that paracrine factors secreted by meningothelial cells can influence migration and adherence of medulloblastoma tumor cells, but VEGFA may not be a specific target for therapeutic intervention in this context.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leptomeningeal metastasis; Medulloblastoma; VEGFA

Mesh:

Substances:

Year:  2014        PMID: 24928387      PMCID: PMC4153354          DOI: 10.1016/j.bbrc.2014.06.018

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Metastatic medulloblastoma--therapeutic success through molecular target identification?

Authors:  M C Frühwald; C Plass
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

2.  Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

Authors:  Dolly G Aguilera; Steward Goldman; Jason Fangusaro
Journal:  Pediatr Blood Cancer       Date:  2011-03       Impact factor: 3.167

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.

Authors:  B van de Langerijt; J M Gijtenbeek; H P M de Reus; F C G J Sweep; A Geurts-Moespot; J C M Hendriks; A C Kappelle; M M Verbeek
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

Review 5.  Cytokine disbalance in common human cancers.

Authors:  Zoran Culig
Journal:  Biochim Biophys Acta       Date:  2010-12-15

6.  Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.

Authors:  G Stockhammer; W Poewe; S Burgstaller; F Deisenhammer; A Muigg; S Kiechl; E Schmutzhard; H Maier; S Felber; P Schumacher; E Gunsilius; G Gastl
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

7.  Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.

Authors:  Matija Snuderl; Ana Batista; Nathaniel D Kirkpatrick; Carmen Ruiz de Almodovar; Lars Riedemann; Elisa C Walsh; Rachel Anolik; Yuhui Huang; John D Martin; Walid Kamoun; Ellen Knevels; Thomas Schmidt; Christian T Farrar; Benjamin J Vakoc; Nishant Mohan; Euiheon Chung; Sylvie Roberge; Teresa Peterson; Carlos Bais; Boryana H Zhelyazkova; Stephen Yip; Martin Hasselblatt; Claudia Rossig; Elisabeth Niemeyer; Napoleone Ferrara; Michael Klagsbrun; Dan G Duda; Dai Fukumura; Lei Xu; Peter Carmeliet; Rakesh K Jain
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

8.  Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.

Authors:  Mariam P Korah; Natia Esiashvili; Claire M Mazewski; Roger J Hudgins; Mourad Tighiouart; Anna J Janss; Frederick P Schwaibold; Ian R Crocker; Walter J Curran; Robert B Marcus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-19       Impact factor: 7.038

9.  Differential expression of VEGF isoforms in mouse during development and in the adult.

Authors:  Y S Ng; R Rohan; M E Sunday; D E Demello; P A D'Amore
Journal:  Dev Dyn       Date:  2001-02       Impact factor: 3.780

10.  Metastatic Medulloblastoma in Childhood: Chang's Classification Revisited.

Authors:  Christelle Dufour; Annick Beaugrand; Barry Pizer; Julie Micheli; Marie-Stephanie Aubelle; Aurelie Fourcade; Dominique Couanet; Agnes Laplanche; Chantal Kalifa; Jacques Grill
Journal:  Int J Surg Oncol       Date:  2011-09-11
View more
  2 in total

1.  Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A.

Authors:  Stephanie Jamison; Yifeng Lin; Wensheng Lin
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 2.  Meninges: A Widespread Niche of Neural Progenitors for the Brain.

Authors:  Ilaria Decimo; Sissi Dolci; Gabriella Panuccio; Marco Riva; Guido Fumagalli; Francesco Bifari
Journal:  Neuroscientist       Date:  2020-09-16       Impact factor: 7.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.